Previous close | 0.0010 |
Open | 0.0010 |
Bid | 0.0000 x N/A |
Ask | 0.0000 x N/A |
Day's range | 0.0010 - 0.0010 |
52-week range | 0.0010 - 1.9690 |
Volume | |
Avg. volume | 1,769 |
Market cap | 39,727 |
Beta (5Y monthly) | 1.97 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.1800 |
Earnings date | 13 May 2024 - 17 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 41.50 |
Following the acquisition, Ligand (LGND) has full ownership rights to berdazimer gel, all assets related to NITRICIL drug delivery technology platform and rights to the Sitavig program.
Ligand (LGND) announces a $15 million bid in cash to acquire all assets of Novan Inc. along with another $15 million loan as debtor-in-possession financing.